Literature DB >> 8646581

Prognostic indicators following enucleation for posterior uveal melanoma. A multivariate analysis of long-term survival with minimized loss to follow-up.

S Seregard1, E Kock.   

Abstract

Most previous reports on survival following enucleation for uveal malignant melanoma do not contain cumulative survival rates, do not use a multivariate approach and are liable to a considerable loss to follow-up. In this study, the long-term survival and tumour-related mortality were studied in 340 patients. Archival specimens containing posterior uveal melanomas were initially examined and sectioned by one pathologist. There was no loss to follow-up 6 to 22 years after enucleation. At the end of study, 233 (68.5%) individuals were dead; 137 (40.3%) of melanoma-related causes and 96 (28.2%) of other causes. Melanoma-related deaths appeared from 24 to 6848 days (18 years 8 months) after enucleation. The cumulative 5-year survival proportion based on melanoma-related deaths was 70% and the corresponding 10-year proportion was 56%. Multivariate Cox regression indicated that the largest tumour dimension, cell type, and tumour location all had independent prognostic value, the associated hazard ratios ranged from 1.2 to 1.4, suggesting a moderate increase of the relative risk. Pair-wise comparisons of the parameters indicated that large tumours were more common in the anterior choroid or ciliary body than in the posterior choroid. Similarly, large tumours were more often necrotic, composed of epitheloid cells, or featured extrascleral extension. Tumours with significant scleral invasion or extrascleral extension were more common in elderly patients.

Entities:  

Mesh:

Year:  1995        PMID: 8646581     DOI: 10.1111/j.1600-0420.1995.tb00039.x

Source DB:  PubMed          Journal:  Acta Ophthalmol Scand        ISSN: 1395-3907


  13 in total

1.  Uveal melanoma-associated survival in Scotland.

Authors:  Aaron Jamison; Lesley A Bhatti; Manvi M Sobti; Vikas Chadha; Paul Cauchi; Ewan G Kemp
Journal:  Eye (Lond)       Date:  2019-10-25       Impact factor: 3.775

Review 2.  Minimally invasive intra-arterial regional therapy for metastatic melanoma: isolated limb infusion and percutaneous hepatic perfusion.

Authors:  Dale Han; Georgia M Beasley; Douglas S Tyler; Jonathan S Zager
Journal:  Expert Opin Drug Metab Toxicol       Date:  2011-10-07       Impact factor: 4.481

3.  True versus mild hyperthermia during isolated hepatic perfusion: effects on melphalan pharmacokinetics and liver function.

Authors:  Pierluigi Pilati; Simone Mocellin; Carlo R Rossi; Carlo Ori; Federico Innocente; Romano Scalerta; Mauro Ceccherini; Pier Paolo Da Pian; Donato Nitti; Mario Lise
Journal:  World J Surg       Date:  2004-08-03       Impact factor: 3.352

Review 4.  Isolated hepatic perfusion for patients with liver metastases.

Authors:  Srinevas K Reddy; Susan B Kesmodel; H Richard Alexander
Journal:  Ther Adv Med Oncol       Date:  2014-07       Impact factor: 8.168

Review 5.  An alternative hypothesis for observed mortality rates due to metastasis after treatment of choroidal melanomas of different sizes.

Authors:  James J Augsburger; Zélia M Corrêa; Nikolaos Trichopoulos
Journal:  Trans Am Ophthalmol Soc       Date:  2007

6.  Uveal Melanoma in Ireland.

Authors:  Caroline Baily; Valerie O'Neill; Mary Dunne; Moya Cunningham; Giuseppe Gullo; Susan Kennedy; Paul M Walsh; Sandra Deady; Noel Horgan
Journal:  Ocul Oncol Pathol       Date:  2018-09-13

7.  Isolated hypoxic hepatic perfusion with retrograde outflow in patients with irresectable liver metastases; a new simplified technique in isolated hepatic perfusion.

Authors:  Cornelis Verhoef; Johannes H W de Wilt; Flavia Brunstein; Andreas W K S Marinelli; Boudewijn van Etten; Maarten Vermaas; Gunther Guetens; Gert de Boeck; Ernst A de Bruijn; Alexander M M Eggermont
Journal:  Ann Surg Oncol       Date:  2008-02-01       Impact factor: 5.344

Review 8.  Uveal melanoma: estimating prognosis.

Authors:  Swathi Kaliki; Carol L Shields; Jerry A Shields
Journal:  Indian J Ophthalmol       Date:  2015-02       Impact factor: 1.848

9.  Forty-year prognosis after plaque brachytherapy of uveal melanoma.

Authors:  Gustav Stålhammar
Journal:  Sci Rep       Date:  2020-07-09       Impact factor: 4.379

10.  Radiobiological doses, tumor, and treatment features influence on local control, enucleation rates, and survival after epiescleral brachytherapy. A 20-year retrospective analysis from a single-institution: part I.

Authors:  David Miguel; Jesús María de Frutos-Baraja; Francisco López-Lara; María Antonia Saornil; Ciro García-Álvarez; Pilar Alonso; Patricia Diezhandino
Journal:  J Contemp Brachytherapy       Date:  2018-08-31
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.